Analysts Offer Insights on Healthcare Companies: Mesoblast Ltd (MESO) and TrovaGene (TROV)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mesoblast Ltd (NASDAQ:MESO) and TrovaGene (NASDAQ:TROV) with bullish sentiments.

Mesoblast Ltd (MESO)

In a report released today, Jason Kolbert from H.C. Wainwright maintained a Buy rating on Mesoblast Ltd, with a price target of $17. The company’s shares closed yesterday at $5.98.

Kolbert observed:

“Our valuation is based on our therapeutic models and reflects our assumptions for the product launch dates, product attributes, and pricing, to determine the future revenue streams. We have not yet factored in China.”

According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -2.7% and a 37.2% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Anavex Life Sciences, and Coherus Biosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mesoblast Ltd with a $18 average price target, which is a 201.0% upside from current levels. In a report released today, Oppenheimer also reiterated a Buy rating on the stock with a $16 price target.

.

See today’s analyst top recommended stocks >>

TrovaGene (TROV)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on TrovaGene, with a price target of $2.50. The company’s shares closed yesterday at $0.80, close to its 52-week low of $0.65.

According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.9% and a 46.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TrovaGene with a $2.75 average price target, a 243.4% upside from current levels. In a report issued on August 16, Maxim Group also maintained a Buy rating on the stock with a $3 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts